Non-animal based approaches to risk assessment are now routinely used for assuring consumer safety for some endpoints (such as skin irritation) following considerable investment in developing and applying new methods over the past 20 years. Unilever's research programme into non-animal approaches for safety assessment is currently focused on the application of new technologies to risk assessments in the areas of skin allergy, cancer and general toxicity (including inhalation toxicity). In all of these areas, a long-term investment is essential to increase the scientific understanding of the underlying biological and chemical processes that we believe will ultimately form a sound basis for novel risk assessment approaches. Our research programme in these priority areas consists of in-house research as well as Unilever-sponsored academic research, involvement with EU-funded projects (e.g. Sens-it-iv, carcino-GENOMICS), participation in cross-industry collaborative research (e.g. COLIPA, EPAA) and ongoing involvement with other scientific initiatives on non-animal approaches to risk assessment (e.g. UK NC3Rs, US ‘Human Toxicology Project’ consortium).
US National Research Council (2007). Toxicity Testing in the 21st Century: A Vision and a Strategy, 216 pp. Washington, DC, USA: The National Academies Press.
4.
FentemJ., ChamberlainM. & SangsterB. (2004). The feasibility of replacing animal testing for assessing consumer safety: a suggested future direction. ATLA32, 617–623.
5.
MaxwellG., AleksicM., AptulaA., CarmichaelP., FentemJ., GilmourN., MacKayC., PeaseC., PendlingtonR., ReynoldsF., ScottD., WarnerG. & WestmorelandC. (2008). Assuring consumer safety without animal testing: A feasibility case study for skin sensitisation. ATLA36, 557–568.
6.
SmithC.K. & HotchkissS.A. (2001). Allergic Contact Dermatitis, pp. 1–16. London, UK: Taylor & Francis.
7.
FelterS.P., RyanC.A., BasketterD.A., GilmourN.J. & GerberickG.F. (2003). Application of the risk assessment paradigm to the induction of allergic contact dermatitis. Regulatory Toxicology & Pharmacology37, 1–10.
SaffordR.J. (2008). The Dermal Sensitisation Threshold — a TTC approach for allergic contact dermatitis. Regulatory Toxicology & Pharmacology51, 195–200.
10.
BasketterD., PeaseC., KastingG., KimberI., CasatiS., CroninM., DiembeckW., GerberickF., HadgraftJ., HartungT., MartyJ.P., NikolaidisE., PatlewiczG., RobertsD., RoggenE., RovidaC. & van de SandtJ. (2007). Skin sensitisation and epidermal disposition: The relevance of epidermal disposition for sensitisation hazard identification and risk assessment. The report and recommendations of ECVAM Workshop 59. ATLA35, 137–154.
11.
PendlingtonR.U., MinterH.J., StupartL., MacKayC., RoperC.S., SandersD.J. & PeaseC.K. (2008). Development of a modified in vitro skin absorption method to study the epidermal/dermal disposition of a contact allergen in human skin. Cutaneous & Ocular Toxicology27, 283–294.
12.
AebyP., AshikagaT., DiembeckW., EstrichD., GerberickF., KimberI., Marrec-FairleyM., MaxwellG., OvigneJ.M., SakaguchiH., TailhardatM. & TessierS. (2008). The COLIPA strategy for the development of in vitro alternatives: Skin sensitisation. AATEX14, 375–379.
13.
NitscheJ.M. & KastingG.B. (2008). Biophysical models for skin transport and absorption. In Dermal Absorption and Toxicity Assessment (ed. RobertsM.S. & WaltersK.A.), pp. 251–269. New York, NY, USA: Informa Healthcare.
14.
MaxwellG. & MacKayC. (2008). Application of a systems biology approach to skin allergy risk assessment. ATLA36, 521–556.
15.
DivkovicM., PeaseC.K., GerberickG.F. & BasketterD.A. (2005). Hapten protein binding: from theory to practical application in the in vitro prediction of skin sensitisation. Contact Dermatitis54, 73–74.
16.
GerberickG.F., VassalloJ.D., FoertschL.M., PriceB.B., ChaneyJ.G. & LepoittevinJ.P. (2007). Quantification of chemical peptide reactivity for screening contact allergens: A classification tree model approach. Toxicological Sciences97, 417–427.
17.
NatschA., GfellerH., RothauptM. & EllisG. (2007). Utility and limitations of a peptide reactivity assay to predict fragrance allergens in vitro. Toxicology in Vitro21, 1220–1226.
18.
KatoH., OkamotoM., YamashitaK., NakamuraY., FukumoriY., NakaiK. & KanekoH. (2003). Peptide-binding assessment using mass spectrometry as a new screening method for skin sensitization. Journal of Toxicological Sciences28, 19–24.
19.
AleksicM., ThainE., RogerD., SaibO., DaviesM., LiJ., AptulaA. & ZazzeroniR. (2009). Reactivity profiling: Covalent modification of single nucleophile peptides for skin sensitization risk assessment. Toxicological Sciences108, 401–411.
20.
AptulaN., RobertsD.W., SchultzT.W. & PeaseC. (2007). Reactivity assays for non-animal based prediction of skin sensitisation potential. Toxicology231, 117–118.
21.
JowseyI.R., BasketterD.A., WestmorelandC. & KimberI. (2006). A future approach to measuring relative skin sensitising potency: a proposal. Journal of Applied Toxicology26, 341–350.
22.
FlynnT.J. & FergusonM.S. (2008). Multiendpoint mechanistic profiling of hepatotoxicants in HepG2/C3A human hepatoma cells and novel statistical approaches for development of a prediction model for acute hepatotoxicity. Toxicology in Vitro22, 1618–1631.
23.
NatschA., EmterR. & EllisG. (2009). Filling the concept with data: integrating data from different in vitro and in silico assays on skin sensitizers to explore the battery approach for animal-free skin sensitization testing. Toxicological Sciences107, 106–121.
24.
RobertsD.W. & WilliamsD.L. (1982). The derivation of quantitative correlations between skin sensitisation and physiochemical parameters for alkylating agents, and their application to experimental data for sultones. Journal of Theoretical Biology99, 807–825.
25.
MaxwellG. & MacKayC. (2008). Application of a systems biology approach for skin allergy risk assessment. AATEX14, 381–388.
26.
DearmanR.J., WrightZ.M., BasketterD.A., RyanC.A., GerberickG.F. & KimberI. (2001). The suitability of hexyl cinnamic aldehyde as a calibrant for the murine local lymph node assay. Contact Dermatitis44, 357–361.
27.
BasketterD.A. & CadbyP. (2004). Reproducible prediction of contact allergenic potency using the local lymph node assay. Contact Dermatitis50, 15–27.
28.
BasketterD.A., McFaddenJ.F., GerberickF., CockshottA. & KimberI. (2009). Nothing is perfect, not even the local lymph node assay: a commentary and the implications for REACH. Contact Dermatitis60, 65–69.
29.
KennedyM.C. (2009). Bayesian modelling of long-term dietary intakes from multiple sources. Food & Chemical Toxicology, 9 October 2009. [E-pub ahead of print].
30.
GerberickG.F., RyanC.A., KernP.S., SchlatterH., DearmanR.J., KimberI., PatlewiczG.Y. & BasketterD.A. (2005). Compilation of historical local lymph node assay data for evaluation of skin sensitization alternative methods. Dermatitis16, 157–202.
31.
BasketterD.A., BlaikieL., DearmanR.J., KimberI., RyanC., GerberickG.F., HarveyP., EvansP., WhiteI.R. & RycroftJ.G. (2000). Use of the local lymph node assay for the estimation of relative contact allergenic potency. Contact Dermatitis42, 344–348.
32.
BasketterD.A., ClappC., JefferiesD., SaffordB., RyanC.A., GerberickG.F., DearmanR.J. & KimberI. (2005). Predictive identification of human skin sensitisation thresholds. Contact Dermatitis53, 260–267.
33.
BasketterD.A. & KimberI. (2007). Information derived from sensitisation test methods: test sensitivity, false positives and false negatives. Contact Dermatitis56, 1–4.
34.
BasketterD.A., McFaddenJ., EvansP., AndersenK.E. & JowseyI. (2006). Identification and classification of skin sensitisers: Identifying false positive and false negatives. Contact Dermatitis55, 268–273.
SchuchA., UterW., GeierJ., LessmannH. & FroschP.J. (2007). Sensitisation to 26 fragrances to be labeled according to current European regulation. Contact Dermatitis57, 1–10.
37.
JowseyI.R. (2007). Proactive surveillance of contact allergies: an important component of the risk management strategy for skin sensitizers. Contact Dermatitis56, 305–310.
38.
SchnuchA., GeierJ., UterW., BasketterD.A. & JowseyI.R. (2007). The biocide polyhexamethylene biguanide remains an uncommon contact allergen. Contact Dermatitis56, 235–239.
39.
TweatsD.J., ScottA.D., WestmorelandC. & CarmichaelP.L. (2007). Determination of genetic toxicology and potential carcinogenicity in vitro —challenges post the Seventh Amendment to the European Cosmetics Directive. Mutagenesis22, 5–13.
40.
KirklandD.J., AardemaM., BanduhnN., CarmichaelP., FautzR., MeunierJ.R. & PfuhlerS. (2007). In vitro approaches to develop weight-of-evidence (WoE) and mode of action (MoA) discussions with positive in vitro genotoxicty results. Mutagenesis22, 161–175.
WilliamsK., FowlerP., JeffreyL., YoungJ., CarmichaelP., AardemaM., DiembeckW., FautzR., HarveyJ., HewittN.J., LatilA., PfuhlerS., QuedraogoG., ReisingerK., Marrec-FairleyM. & KirklandD. (2009). Reduction of misleading (“false”) positive results in mammalian cell genotoxicity assays. II: Importance of accurate toxicity measurement. ALTEX26, 189.
44.
ScottA., MalcomberS., MaskellS., MooreC., WindebankS., DiazD. & CarmichaelP. (2007). An assessment of the performance of an automated scoring system (Cellomics) for the in vitro micronucleus assay in CHO-K1 cells. Toxicology231, 111–112.
45.
WindebankS., MalcomberS., MaskellS., ScottA. & CarmichaelP. (2006). Validation of a high-throughput bacterial screen for mutagenicity: Incorporation of Salmonella typhimurium strain TA102. [Proceedings of the British Toxicological Society & United Kingdom Environmental Mutagen Society Congress, Warwick, UK]. Toxicology226, 72–73.
46.
Kirsch-VoldersM., GonzalezL., CarmichaelP. & KirklandD. (2009). Risk assessment of genotoxic mutagens with thresholds: A brief introduction. Mutation Research678, 72–75.
47.
CarmichaelP., Kirsch-VoldersM. & VrijhofH. (2009). Thresholds for genotoxins and their application in risk assessment. Mutation Research678, 71.
48.
MaskellS., MalcomberS., WindebankS., CarmichaelP. & ScottA. (2006). Development of a human keratinocyte cell line that is up-regulated for the expression of Superoxide Dismutase 1 (SOD1). [Proceedings of the British Toxicological Society & United Kingdom Environmental Mutagen Society Congress, Warwick, UK]. Toxicology, 226, 74–75.
49.
PantK., SlyJ.E., BruceS.W., LeungC. & SanR.H. (2008). Syrian hamster embryo (SHE) cell transformation assay with conditioned media (without X-ray irradiated feeder layer) using 2,4-diaminotoluene, 2,6-diaminotoluene and chloral hydrate. Mutation Research654, 108–113.
50.
WalshM.J., BruceS.W., PantK., CarmichaelP.L., ScottA.D. & MartinF.L. (2009). Discrimination of a transformed phenotype in Syrian golden hamster embryo (SHE) cells using ATR-FTIR spectroscopy. Toxicology258, 33–38.
51.
TitmanC.M., DownsJ.A., OliverS.G., CarmichaelP.L., ScottA.D. & GriffinJ.L. (2009). A metabolomic and multivariate statistical process to assess the effects of genotoxins in Saccharomyces cerevisiae. Molecular BioSystems5, 1913–1924.
52.
BillintonN., HastwellP.W., BeerensD., BirrellL., EllisP., MaskellS., WebsterT.W., WindebankS., WoestenborghsF., LynchA.M., ScottA.D., TweatsD.J., van GompelJ., ReesR.W. & WalmsleyR.M. (2008). Inter-laboratory assessment of the Green-Screen HC GADD45a-GFP genotoxicity screening assay: An enabling study for independent validation as an alternative method. Mutation Research653, 23–33.
53.
KnightA.W., BillintonN., CahillP.A., ScottA., HarveyJ.S., RobertsK.J., TweatsD.J., KeenanP.O. & WalmsleyR.M. (2007). An analysis of results from 305 compounds tested with the yeast RAD54-GFP genotoxicity assay (GreenScreen GC) — including relative predictivity of regulatory tests and rodent carcinogenesis and performance with autofluorescent and coloured compounds. Mutagenesis22, 409–416.
54.
BillintonN., BeerensD., BirrellL., van GompelJ., HastwellP.W., ReesR., ScottA., WalmsleyR.M., WebsterT.W., WindebankS. & WoestenborghsF. (2006). An international, 4 laboratory assessment of the robustness and reproducibility of the GADD45a genotoxicity assay, GreenScreenHC. Environmental & Molecular Mutagenesis47, 434.
55.
WhitworthT., ScottA. & WalmsleyR.M. (2006). Further development of a yeast genotoxicity assay to improve the spectrum of compound detection. Environmental & Molecular Mutagenesis47, 471.
56.
VinkenM., DoktorovaT., Ellinger-ZiegelbauerH., AhrH.J., LockE., CarmichaelP., RoggenE., van DelftJ., KleinjansJ., CastellJ., BortR., DonatoT., RyanM., CorviR., KeunH., EbbelsT., AthersuchT., SansoneS.A., Rocca-SerraP., StierumR., JenningsP., PfallerW., GmuenderH., VanhaeckeT. & RogiersV. (2008). The carcinoGENOMICS project: Critical selection of model compounds for the development of omics-based in vitro carcinogenicity screening assays. Mutation Research659, 202–210.
57.
Ellinger-ZiegelbauerH., FostelJ.M., ArugaC., BauerD., BoitierE., DengS., DickinsonD., Le FevreA.C., FornaceA.J.Jr, GrenetO., GuY., HoflackJ.C., ShiiyamaM., SmithR., SnyderR.D., SpireC., TanakaG. & AubrechtJ. (2009). Characterization and interlaboratory comparison of a gene expression signature for differentiating genotoxic mechanisms. Toxicological Sciences110, 341–352.
58.
QuirósL., SvenssonP., WangE., FryR. & SamsonL. (2008). Analysing genetic interactions to elucidate DNA damage responsive networks and toxicity mechanisms of environmental agents in yeast. [Abstract: Environmental Mutagen Society Conference, Puerto Rico.] Environmental & Molecular Mutagenesis49, 578.
59.
ShannonP., MarkielA., OzierO., BaligaN.S., WangJ.T., RamageD., AminN., SchwikowskiB. & IdekerT. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Research13, 2498–2504.
60.
WhiteA., DonaldsonK., GaiserB., DalyP., BéruBéK., HughesT., MerollaL., CarthewP., AdeleyeY. & FletcherS. (2009). A mechanistic comparison of in vitro and in vivo studies of lung toxicity using transcriptomic analysis. ALTEX26, 74.
61.
CarthewP., FletcherS., WhiteA., HarriesH. & WeberK. (2006). Transcriptomic and histopathology changes in rat lung after intratracheal instillation of polymers. Inhalation Toxicology18, 227–245.
62.
GraingerC.I., GreenwellL.L., MartinG.P. & ForbesB. (2009). Hydrophilic solute permeability following particle delivery to air-interfaced airway cells that model the respiratory mucosa. European Journal of Pharmaceutics & Biopharmaceutics, in press.
63.
GraingerC.I., GreenwellL.L., MartinG.P. & ForbesB. (2009). The permeability of large molecular weight solutes following particle delivery to air-interfaced cells that model the respiratory mucosa. European Journal of Pharmaceutics & Biopharmaceutics71, 318–324.
64.
GraingerC.I., GreenwellL.L., LockleyD.J., MartinG.P. & ForbesB. (2006). Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier. Pharmaceutical Research23, 1482–1490.
65.
HughesT.G. (2009). The Use of In Vitro Human Tissue Equivalents of Respiratory Epithelia for Toxicological Applications [PhD Thesis], pp. 75–139. Cardiff, Wales: Cardiff University.
66.
BéruBéK., AufderheideM., BrehenyD., ClothierR., CombesR., DuffinR., ForbesB., GaçaM., GrayA., HallI., KellyM., LethemM., LiebschM., MerollaL., MorinJ-P., SeagraveJ., SwartzM., TetleyT. & UmachandranM. (2009). In vitro models of inhalation toxicity and disease: The report of a FRAME workshop. ATLA37, 89–141.
67.
KimberI., AgiusR., BasketterD.A., CorsiniE., CullinanP., DearmanR.J., Gimenez-ArnauE., GreenwellL., HartungT., KuperF., MaestrelliP., RoggenE. & RovidaC. (2007). Chemical respiratory allergy: Opportunities for hazard identification and characterisation. The report and recommendations of ECVAM Workshop 60. ATLA35, 243–265.
68.
CarthewP., ClappC. & GutsellS. (2009). Exposure-based waiving: The application of the toxicological threshold of concern (TTC) to inhalation exposure for aerosol ingredients in consumer products. Food & Chemical Toxicology47, 1287–1295.
European Commission (2009). Call for proposals under the 2009 and 2010 work programmes of the 7th EC Framework Programme for Research, Technological Development and Demonstration Activities 2009/C 177/06: FP7-HEALTH-2010-Alternative-Testing. Official Journal of the European Union52, 16.
71.
CretonS., BillingtonR., DaviesW., DentM., HawksworthG., ParryS. & TravisK. (2009). Application of toxicokinetics to improve chemical risk assessment: Implications for the use of animals. Regulatory Toxicology & Pharmacology55, 291–299.
72.
WestmorelandC. & HolmesA.M. (2009). Assuring consumer safety without animals: Applications for tissue engineering. Organogenesis5, 67–72.
73.
EPAA (undated). Activities: Validation and Acceptance.Brussels, Belgium: The European Partnership for Alternative Approaches to Animal Testing. Available at: http://ec.europa.eu/enterprise/epaa/3_6_validation.htm (Accessed 10.12.09).
